[go: up one dir, main page]

AU2001245295A1 - Methods and compositions for the identification, assessment, prevention and therapy of human cancers - Google Patents

Methods and compositions for the identification, assessment, prevention and therapy of human cancers

Info

Publication number
AU2001245295A1
AU2001245295A1 AU2001245295A AU4529501A AU2001245295A1 AU 2001245295 A1 AU2001245295 A1 AU 2001245295A1 AU 2001245295 A AU2001245295 A AU 2001245295A AU 4529501 A AU4529501 A AU 4529501A AU 2001245295 A1 AU2001245295 A1 AU 2001245295A1
Authority
AU
Australia
Prior art keywords
assessment
therapy
prevention
compositions
identification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001245295A
Inventor
Frederick P. Roth
Andrew W. Shyjan
Christophe Van Huffel
James V. White
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
MILLENNIUM PREDICTIVE MEDICINE
MILLENNIUM PREDICTIVE MEDICINE Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MILLENNIUM PREDICTIVE MEDICINE, MILLENNIUM PREDICTIVE MEDICINE Inc filed Critical MILLENNIUM PREDICTIVE MEDICINE
Publication of AU2001245295A1 publication Critical patent/AU2001245295A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6834Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001245295A 2000-02-17 2001-02-16 Methods and compositions for the identification, assessment, prevention and therapy of human cancers Abandoned AU2001245295A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18326500P 2000-02-17 2000-02-17
US60/183,265 2000-02-17
PCT/US2001/005301 WO2001061050A2 (en) 2000-02-17 2001-02-16 Methods and compositions for the identification, assessment, prevention and therapy of human cancers

Publications (1)

Publication Number Publication Date
AU2001245295A1 true AU2001245295A1 (en) 2001-08-27

Family

ID=22672111

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001245295A Abandoned AU2001245295A1 (en) 2000-02-17 2001-02-16 Methods and compositions for the identification, assessment, prevention and therapy of human cancers

Country Status (3)

Country Link
US (2) US20020120004A1 (en)
AU (1) AU2001245295A1 (en)
WO (1) WO2001061050A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050836A1 (en) * 1998-05-01 2008-02-28 Isabelle Guyon Biomarkers for screening, predicting, and monitoring benign prostate hyperplasia
US7434305B2 (en) * 2000-11-28 2008-10-14 Knowles Electronics, Llc. Method of manufacturing a microphone
US20090215058A1 (en) * 2001-01-24 2009-08-27 Health Discovery Corporation Methods for screening, predicting and monitoring prostate cancer
US20090226915A1 (en) * 2001-01-24 2009-09-10 Health Discovery Corporation Methods for Screening, Predicting and Monitoring Prostate Cancer
US20090215024A1 (en) * 2001-01-24 2009-08-27 Health Discovery Corporation Biomarkers upregulated in prostate cancer
JP2006505256A (en) * 2002-05-17 2006-02-16 ベイラー カレッジ オブ メディスン Different gene expression patterns to predict the chemical sensitivity and chemical resistance of docetaxel
EP1564305A3 (en) * 2004-02-12 2005-08-24 Institut Curie Means for detecting and treating cancer cells resistant to therapeutic agents
EP1828917A4 (en) * 2004-11-12 2012-04-25 Health Discovery Corp Biomarkers for screening, predicting, and monitoring prostate disease
CN102747140A (en) * 2004-12-08 2012-10-24 安万特药物公司 Method for measuring resistance or sensitivity to docetaxel
WO2011135459A2 (en) 2010-04-29 2011-11-03 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy
US10392667B2 (en) 2013-06-07 2019-08-27 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients
US20180087113A1 (en) 2016-09-27 2018-03-29 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
AU2018202878A1 (en) 2017-05-16 2018-12-06 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
AU2019200325A1 (en) 2018-01-31 2019-08-15 Liplasome Pharma Aps Methods for treating cancer and predicting drug responsiveness in cancer patients
US20210222252A1 (en) 2018-05-15 2021-07-22 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
US10835531B1 (en) 2019-06-18 2020-11-17 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2021212305A1 (en) 2020-01-31 2022-08-11 Allarity Therapeutics Europe ApS Methods for predicting ixabepilone responsiveness in cancer patients

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL137371A0 (en) * 1998-01-26 2001-07-24 Schering Ag Gene expression methods for screening compounds
WO1999065928A2 (en) * 1998-06-19 1999-12-23 Genzyme Corporation Polynucleotide population isolated from non-metastatic and metastatic breast tumor tissues

Also Published As

Publication number Publication date
WO2001061050A3 (en) 2003-02-27
US20020120004A1 (en) 2002-08-29
WO2001061050A2 (en) 2001-08-23
US20030129629A1 (en) 2003-07-10

Similar Documents

Publication Publication Date Title
AU2002322280A1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2001236519A1 (en) Identification, assessment, prevention, and therapy of prostate cancer
AU6147401A (en) Compositions and methods for the treatment of cancer
AU2001251613A1 (en) Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers
AU2001229340A1 (en) Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2001268259A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2001269766A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2002219782A1 (en) Diindolylmethane and c-substituted diindolylmethane compositions and methods for the treatment of multiple cancers
AU2495200A (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2001245295A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
AU2001280982A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2002303219A1 (en) Compositions and methods for the therapy and diagnosis of cancer
AU2002246519A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU7701100A (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
IL158206A0 (en) Compositions and methods for the prevention and treatment of human prostate cancer
AU2002257033A1 (en) Agents and methods for the prevention of initial onset and recurrence of existing cancers
AU2001238493A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
AU2074101A (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
AU2596901A (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2001259062A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2002241720A1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
AU2001290518A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer